

**AMENDMENT TO THE CLAIMS**

This listing of claims will replace all prior versions, and listings, of claims in the application.

***Listing of claims:***

1. (Currently amended) A pharmaceutical composition for application to the mucosa comprising as the sole active ingredients a combination of
  - a.) 4-[(4-chlorophenyl)methyl]-2-(hexahydro-1-methyl-1H-azepin-4-yl)-1(2H)phthalazinone (AZELASTINE), or a stereoisomer, a pharmaceutically acceptable salt or physiologically functional derivative thereof, and
  - b.) ciclesonide, or a pharmaceutically acceptable salt of ciclesonide, an epimer of ciclesonide, or a physiologically functional derivative of ciclesonide,and a pharmaceutically acceptable carrier and/or one or more excipients, wherein said pharmaceutical composition has an osmotic pressure of less than 290 mOsm.
2. (Canceled)
3. (Previously presented) The pharmaceutical composition for application to the mucosa according to claim 1, wherein said osmotic pressure is 150 mOsm or less.
4. (Previously presented) The pharmaceutical composition for application to the mucosa according to claim 1, wherein said osmotic pressure is 60 mOsm or less.

5. (Previously presented) The pharmaceutical composition for application to the mucosa according to claim 1, wherein said osmotic pressure is 40 mOsm or less.
6. (Previously presented) The pharmaceutical composition for application to the mucosa according to claim 1, wherein said osmotic pressure is 20 mOsm or less.
7. (Previously presented) The pharmaceutical composition for application to the mucosa according to claim 1, further comprising an osmotic pressure-controlling agent.
8. (Previously presented) The pharmaceutical composition for application to the mucosa according to claim 1, further comprising a water-insoluble and/or water-low soluble substance.
9. (Previously presented) The pharmaceutical composition for application to the mucosa according to claim 21, wherein said cellulose is microcrystalline cellulose.
10. (Previously presented) The pharmaceutical composition for application to the mucosa according to claim 8, wherein said one or more water-insoluble and/or water-low soluble substances is/are present as solid particles in an aqueous medium.
11. (Previously presented) The pharmaceutical composition for application to the mucosa according to claim 1, further comprising a water-soluble polymer substance.

12. (Previously presented) The pharmaceutical composition for application to the mucosa according to claim 11, wherein a combination of said water-insoluble substance and water-soluble polymer is present which is microcrystalline cellulose and carboxymethyl cellulose sodium.

13. (Previously presented) The pharmaceutical composition for application to the mucosa according to claim 1, further comprising a surfactant and/or a wetting agent.

14. (Previously presented) The pharmaceutical composition for application to the mucosa according to claim 1, wherein said mucosa is nasal mucosa.

15 - 17. (Canceled)

18. (Currently amended) A method for the treatment of allergic rhinitis and/or allergic conjunctivitis in a mammal, which comprises administration of a therapeutically effective amount of a pharmaceutical formulation comprising as the sole active ingredients a combination of

a.) 4-[(4-chlorophenyl)methyl]-2-(hexahydro-1-methyl-1H-azepin-4-yl)-

1(2H)phthalazinone (AZELASTINE) or a stereoisomer, a pharmaceutically acceptable salt or physiologically functional derivative thereof, and

b.) ciclesonide, or a pharmaceutically acceptable salt of ciclesonide, an epimer of ciclesonide, or physiologically functional derivative of ciclesonide thereof,

and a pharmaceutically acceptable carrier and/or one or more excipients, wherein said pharmaceutical formulation has an osmotic pressure of less than 290 mOsm.

19. (Previously presented) The pharmaceutical composition according to claim 1, wherein said epimer of ciclesonide is [11 $\beta$ ,16 $\alpha$ (S)]-16,17-[(cyclohexylmethylen)bis(oxy)]-11-hydroxy-21-(2-methyl-1-oxopropoxy)-pregna-1,4-dien-3,20-dion and is present in any mixing ratio with ciclesonide, [11 $\beta$ ,16 $\alpha$ (R)]-16,17-[(cyclohexylmethylen)bis(oxy)]-11-hydroxy-21-(2-methyl-1-oxopropoxy)-pregna-1,4-dien-3,20-dion.

20. (Previously presented) The method of claim 18, wherein said mammal is a human.

21. (Previously presented) The pharmaceutical composition for application to the mucosa according to claim 8, wherein said water-insoluble and/or water-low soluble substance is a cellulose.

22. (Currently amended) The pharmaceutical composition for application to the mucosa according to claim 1, wherein the sole active ingredients are ~~agent is~~ a combination of azelastine or a pharmaceutically acceptable salt thereof, and ciclesonide, or a pharmaceutically acceptable salt of ciclesonide, an epimer of ciclesonide, or a physiologically functional derivative of ciclesonide, ~~and a pharmaceutically acceptable carrier and/or one or more excipients.~~

23. (Previously presented) The pharmaceutical composition for application to the mucosa according to claim 1, wherein the pharmaceutically acceptable salt of azelastine is azelastine hydrochloride.

24. (Previously presented) The pharmaceutical composition for application to the mucosa according to claim 1, wherein ciclesonide is [11 $\beta$ ,16 $\alpha$ (R)]-16,17-[(cyclohexylmethylen)bis(oxy)]-11-hydroxy-21-(2-methyl-1-oxopropoxy)-pregna-1,4-dien-3,20-dion.

25. (Currently amended) The pharmaceutical composition for application to the mucosa according to claim 1, wherein the sole active ingredients are ~~agent is~~ a combination of azelastine or a pharmaceutically acceptable salt thereof and ciclesonide.

26. (Currently amended) The pharmaceutical composition for application to the mucosa according to claim 1, wherein the sole active ingredients are ~~agent is~~ a combination of azelastine hydrochloride and ciclesonide.

27. (Currently amended) The method for the treatment of allergic rhinitis and/or allergic conjunctivitis in a mammal according to claim 18, wherein the sole active ingredients are ~~agent is~~ a combination of azelastine or a pharmaceutically acceptable salt thereof and ciclesonide, or a pharmaceutically acceptable salt of ciclesonide, an epimer of ciclesonide, or a physiologically functional derivative of ciclesonide, ~~and a pharmaceutically acceptable carrier and/or one or more excipients.~~

28. (Previously presented) The method for the treatment of allergic rhinitis and/or allergic conjunctivitis in a mammal according to claim 18, wherein the pharmaceutically acceptable salt of azelastine is azelastine hydrochloride.

29. (Previously presented) The method for the treatment of allergic rhinitis and/or allergic conjunctivitis in a mammal according to claim 18, wherein ciclesonide is [11 $\beta$ ,16 $\alpha$ (R)]-16,17-[(cyclohexylmethylen)bis(oxy)]-11-hydroxy-21-(2-methyl-1-oxopropoxy)-pregna-1,4-dien-3,20-dion.

30. (Currently amended) The method for the treatment of allergic rhinitis and/or allergic conjunctivitis in a mammal according to claim 18, wherein the sole active ingredients are ~~agent is~~ a combination of azelastine or a pharmaceutically acceptable salt thereof and ciclesonide.

31. (Currently amended) The method for the treatment of allergic rhinitis and/or allergic conjunctivitis in a mammal according to claim 18, wherein the sole active ingredients are ~~agent is~~ a combination of azelastine hydrochloride and ciclesonide.